Charles Schwab
PRVL

Charles Schwab’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Charles Schwab’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-33,282
Closed -$768K – 3550
2020
Q4 		$768K Hold
33,282
– – ﹤0.01% 2856
2020
Q3 		$339K Sell
33,282
-1,724
-5% -$23.1K ﹤0.01% 2992
2020
Q2 		$522K Buy
35,006
+5,290
+18% +$81.5K ﹤0.01% 2813
2020
Q1 		$363K Buy
29,716
+14,054
+90% +$224K ﹤0.01% 2818
2019
Q4 		$248K Hold
15,662
– – ﹤0.01% 3012
2019
Q3 		$193K Buy
+15,662
New +$177K ﹤0.01% 3045

Charles Schwab's PRVL Position: Q1 2021 in Review

Charles Schwab sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 33,282 shares — an estimated $768K sold.

Charles Schwab first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $768K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Charles Schwab reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Charles Schwab sold 33,282 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $768K.
  • Charles Schwab first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • Charles Schwab's Prevail Therapeutics Inc. Common Stock position peaked at $768K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.